Top Page
Envoy Medical
(NASDAQ:COCH)
Envoy Medical (COCH) vs. SPDR S&P 500 ETF (SPY)
Envoy Medical Business Overview & Revenue Model
Envoy Medical Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 208.00K | 225.00K | 316.00K | 237.00K | 310.00K |
| Gross Profit | -612.00K | -517.00K | -473.00K | -261.00K | -459.00K |
| EBITDA | -19.54M | -19.81M | -29.79M | -8.63M | -6.80M |
| Net Income | -21.79M | -20.80M | -29.92M | -15.92M | -8.68M |
Balance Sheet | |||||
| Total Assets | 8.18M | 11.54M | 8.27M | 2.56M | 2.62M |
| Cash, Cash Equivalents and Short-Term Investments | 3.56M | 5.48M | 4.22M | 183.00K | 1.12M |
| Total Debt | 946.00K | 19.66M | 562.00K | 34.53M | 23.48M |
| Total Liabilities | 15.71M | 30.38M | 10.05M | 38.75M | 47.58M |
| Stockholders Equity | -7.53M | -18.84M | -1.78M | -36.20M | -44.96M |
Cash Flow | |||||
| Free Cash Flow | -16.38M | -18.93M | -17.24M | -9.02M | -7.06M |
| Operating Cash Flow | -16.90M | -17.95M | -17.09M | -8.80M | -6.94M |
| Investing Cash Flow | 527.00K | -980.00K | -153.00K | -218.00K | -125.00K |
| Financing Cash Flow | 15.51M | 20.20M | 21.28M | 8.09M | 8.06M |
Envoy Medical Technical Analysis
Envoy Medical Risk Analysis
Envoy Medical Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
53 Neutral | $36.14M | -4.57 | -95.39% | ― | 145.48% | 67.36% | |
52 Neutral | $75.91M | -3.54 | ― | ― | ― | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $17.71M | -1.26 | -335.47% | ― | 18.76% | 60.09% | |
42 Neutral | $22.13M | ― | ― | ― | -25.18% | -9.71% | |
37 Underperform | $16.92M | ― | -210.36% | ― | -70.54% | 70.03% |
Envoy Medical Corporate Events
On October 27, 2025, Envoy Medical announced that the Nasdaq Hearings Panel granted the company an extension for continued listing on the Nasdaq Stock Market. This decision was influenced by Envoy Medical’s recent equity capital raises, debt extinguishment, and the FDA’s approval to advance to the final stage of the Acclaim® cochlear implant clinical trial. The company has until February 23, 2026, to comply fully with Nasdaq Listing Rule 5550(b)(2), during which it will continue to update Nasdaq and the public on its compliance progress.
The most recent analyst rating on (COCH) stock is a Sell with a $1.00 price target. To see the full list of analyst forecasts on Envoy Medical stock, see the COCH Stock Forecast page.
Study Overview: Envoy Medical, Inc. is conducting a pivotal clinical trial titled ‘Pivotal Clinical Trial Evaluating the Safety and Efficacy of the Fully Implanted Acclaim Cochlear Implant.’ The study aims to assess the effectiveness and safety of the Acclaim Cochlear Implant (CI) in treating severe to profound sensorineural hearing loss in adults. Key objectives include determining if the device improves word recognition and identifying any medical issues post-implantation.
On October 7, 2025, Envoy Medical entered into a Securities Purchase Agreement to issue and sell 3,007,524 shares of Class A common stock at $1.33 per share, raising approximately $4 million in a registered direct offering. Concurrently, the company issued warrants to purchase up to 9,022,572 shares, potentially generating an additional $12 million if fully exercised. The proceeds are intended for working capital and general corporate purposes, with H.C. Wainwright & Co. acting as the exclusive placement agent.
The most recent analyst rating on (COCH) stock is a Sell with a $1.00 price target. To see the full list of analyst forecasts on Envoy Medical stock, see the COCH Stock Forecast page.
On October 7, 2025, Envoy Medical announced that it received FDA approval to advance its pivotal clinical trial for the Acclaim® cochlear implant to the final stage, following promising three-month data from the initial participants. This approval allows the company to expedite its timeline by three to six months and reduce its capital needs by $10-$15 million, positioning Envoy Medical to potentially redefine the cochlear implant market by addressing the needs of a largely untapped market of U.S. adults who prefer fully implanted devices over traditional external hardware.
The most recent analyst rating on (COCH) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on Envoy Medical stock, see the COCH Stock Forecast page.
On September 22, 2025, Envoy Medical announced a Securities Purchase Agreement with investors for a registered direct offering of 1,908,402 shares of Class A common stock at $1.31 per share, expected to close on September 23, 2025. The offering is anticipated to generate approximately $2.5 million in gross proceeds, with potential additional proceeds of $7.5 million if warrants are fully exercised. The funds will be used for working capital and general corporate purposes, and the issuance positions Envoy Medical to strengthen its financial standing and operational capabilities.
The most recent analyst rating on (COCH) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on Envoy Medical stock, see the COCH Stock Forecast page.
On September 19, 2025, Envoy Medical announced the receipt of a European patent for its breakthrough cochlear implant technology, strengthening its global patent portfolio. This patent, effective September 17, 2025, covers advanced signal processing for middle ear sensors, enhancing the company’s position in developing fully implanted hearing devices. The new patent supports Envoy Medical’s mission to deliver life-changing solutions for those with disabling hearing loss, potentially shifting the treatment paradigm for severe to profound sensorineural hearing loss.
The most recent analyst rating on (COCH) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on Envoy Medical stock, see the COCH Stock Forecast page.
Envoy Medical, Inc. received a deficiency notification from Nasdaq on February 25, 2025, due to not meeting the minimum market value of listed securities requirement. Despite a 180-day period to regain compliance, the company failed to meet the requirement by August 26, 2025, and requested a hearing to discuss potential pathways to compliance, including recent financial restructuring, though there is no assurance of a favorable outcome.
The most recent analyst rating on (COCH) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on Envoy Medical stock, see the COCH Stock Forecast page.
On August 25, 2025, Envoy Medical, Inc. entered into a Satisfaction Agreement with GAT Funding, LLC, extinguishing over $32 million in debt for a one-time payment of $100,000. This financial restructuring strengthens Envoy Medical’s balance sheet, allowing the company to focus on developing its lead product, the Acclaim cochlear implant. Additionally, Glen A. Taylor, the company’s largest stockholder and owner of GAT Funding, announced his retirement from the board, marking the end of nearly two decades of service. The move is expected to simplify the company’s capital structure and enhance its growth prospects.
The most recent analyst rating on (COCH) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on Envoy Medical stock, see the COCH Stock Forecast page.